title: Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.
abstract: Fabry disease is an X-linked genetic disorder characterized by deficient activity of α-galactosidase A (GLA) and accumulation of glycolipids, and various GLA gene mutations lead to a wide range of clinical phenotypes from the classic form to the later-onset one. To investigate the biochemical heterogeneity and elucidate the basis of the disease using available clinical samples, we measured GLA activity, GLA protein and accumulated globotriaosylsphingosine (Lyso-Gb3), a biomarker of this disease, in plasma samples from Fabry patients. The analysis revealed that both the enzyme activity and the protein level were apparently decreased, and the enzyme activity was well correlated with the protein level in many Fabry patients. In these cases, a defect of biosynthesis or excessive degradation of mutant GLAs should be involved in the pathogenesis, and the residual protein level would determine the accumulation of Lyso-Gb3 and the severity of the disease. However, there are some exceptional cases, i.e., ones harboring p.C142Y, p.R112H and p.M296I, who exhibit a considerable amount of GLA protein. Especially, a subset of Fabry patients with p.R112H or p.M296I has been attracted interest because the patients exhibit almost normal plasma Lyso-Gb3 concentration. Structural analysis revealed that C142Y causes a structural change at the entrance of the active site. It will lead to a complete enzyme activity deficiency, resulting in a high level of plasma Lyso-Gb3 and the classic Fabry disease. On the other hand, it is thought that R112H causes a relatively large structural change on the molecular surface, and M296I a small one in a restricted region from the core to the surface, both the structural changes being far from the active site. These changes will cause not only partial degradation but also degeneration of the mutant GLA proteins, and the degenerated enzymes exhibiting small and residual activity remain and probably facilitate degradation of Lyso-Gb3 in plasma, leading to the later-onset phenotype. The results of this comprehensive analysis will be useful for elucidation of the basis of Fabry disease.
authors.affiliation: Department of Functional Bioanalysis, Meiji Pharmaceutical University, Tokyo, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Tsukimura
authors.affiliation: Department of Molecular Medical Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; Synthera Technologies, Co., Ltd., Tokyo, Japan.
authors.forename: Sachie
authors.initials: S
authors.lastname: Nakano
authors.affiliation: Department of Functional Bioanalysis, Meiji Pharmaceutical University, Tokyo, Japan.
authors.forename: Tadayasu
authors.initials: T
authors.lastname: Togawa
authors.affiliation: Department of Clinical Genetics, Meiji Pharmaceutical University, Tokyo, Japan.
authors.forename: Toshie
authors.initials: T
authors.lastname: Tanaka
authors.affiliation: Department of Medical Management and Informatics, Hokkaido Information University, Hokkaido, Japan.
authors.forename: Seiji
authors.initials: S
authors.lastname: Saito
authors.affiliation: NPO for the Promotion of Research on Intellectual Property Tokyo, Tokyo, Japan.
authors.forename: Kazuki
authors.initials: K
authors.lastname: Ohno
authors.affiliation: Department of Molecular Medical Research, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
authors.forename: Futoshi
authors.initials: F
authors.lastname: Shibasaki
authors.affiliation: Department of Clinical Genetics, Meiji Pharmaceutical University, Tokyo, Japan.
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sakuraba
keywords: Fabry disease; Globotriaosylsphingosine; Structural modeling; α-Galactosidase A